Mutations in the ASXL1, SRSF2, EZH2, and IDH1/2 genes, referred to as high-risk mutations (HRM), identify patients who have a higher risk of transformation to AML or a higher risk of death (Vannucchi et al., 2013). This evidence concerns the gene IDH1 and acute myeloid leukemia.